IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of ILSE BARTKE, JÜRGEN UNGER, CLAUDE GENAIN and STEPHEN HAUSER U.S. National Phase of PCT/EP98/02029 International Filing Date: 8 April 1998 Priority Date Claimed: 11 April 1997 For: NGF FOR THE PREVENTION OF DEMYELINATION IN THE NERVOUS SYSTEM	Group Art Unit: ART UNIT Examiner: EXAMINER San Francisco, California

Patent Application
Assistant Commissioner of Patents
Washington, D.C. 20231

By Express Mail No: **EL350402892US**
Dated: September 28, 1999

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Sir:

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.

2. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith.

3. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) have not been made and will not be made.

All correspondence regarding this matter should be addressed to:

Customer No.:

020227

PATENT TRADEMARK OFFICE

The filing fee will be deferred at this time.

Dated: September 28, 1999.

Respectfully submitted,

Tom Hunter (Reg. No. 38,498)
MAJESTIC, PARSONS, SIEBERT & HSUE P.C.
Four Embarcadero Center, Suite 1100
San Francisco, California 94111-4106
Telephone: (415) 248-5500
Facsimile: (415) 362-5418

Atty. Docket: 3200.009US0
UCSF Ref. 2000-012

LAW OFFICES OF
MAJESTIC, PARSONS, SIEBERT & HSUE
A PROFESSIONAL CORPORATION
FOUR EMBARCADERO CENTER, SUITE 1100
SAN FRANCISCO, CALIFORNIA 94111-4106
TELEPHONE (415) 248-5500
TELECOPY (415) 362-5418

INTELLECTUAL PROPERTY LAW
PATENTS, TRADEMARKS, COPYRIGHTS,
TRADE SECRETS, AND UNFAIR COMPETITION

SILICON VALLEY OFFICE:
SANTA CLARA, CALIFORNIA

December 15, 2000

United States Department of Commerce
Patent and Trademark office
Assistant Commissioner for Patents
Box PCT
Washington, D.C. 20231

Re: Misdirected Notification of Missing Requirements

Dear Sir/Madam:

The enclosed Notification concerning Application Serial No. 09/529,369 was sent to Majestic, Parsons, Siebert & Hsue, P.C. in error. We have no record of the Application in our docket system. Please redirect the enclosed document. Thank you.

Sincerely,

MAJESTIC, PARSONS, SIEBERT & HSUE P.C.

Roslyn Rhodes

Roslyn Rhodes

Enclosures
rcr

I hereby certify that his correspondence is being deposited via Facsimile to 703 308-6459
On
March 13, 2001

LAW OFFICES OF JONATHAN ALAN QUINE

By

CHANGE OF CORRESPONDENCE ADDRESS *Application*	U.S. Application Number	09/529,369
	Filing Date	8 April 98
	First Named Inventor	BARKTE *et al.*
	Group Art Unit	unassigned
Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Examiner	Anthony Smith
	Attorney Docket Number	3200.009US0

Please change the Correspondence Address for the above-identified application
To:

☑ Customer Number: 22798

22798

PATENT TRADEMARK OFFICE

THAT IS

☐ Firm or Individual Name and Address as shown below:

LAW OFFICES OF JONATHAN ALAN QUINE
P.O. BOX 458
Alameda, California 94501
United States of America
Phone: (510) 337-7871
Fax: (510) 337-7877

I am the:

☐ Applicant

☐ Assignee of record of the entire interest. (Certificate under 37 CFR 3.73(b) is enclosed.)

☑ Attorney or agent of record.

Typed or Printed Name: Tom Hunter, Reg. No. 38,498

Signature:

Date: March 13, 2001

09/529369
PCT/EP98/02029
5/PRTS
426 Rec'd PCT/PTO 28 SEP 1999

NGF for the prevention of demyelination in the nervous system

The present invention concerns a process for prevention of demyelination in the nervous system by administering NGF. In addition, the invention concerns a pharmaceutical composition for treating diseases in which a demyelination of nerve fibers occurs as well as a process for its production.

The covering of nerve fibers in the nervous system (NS) with myelin is essential for the function of neuronal signal transmission. The myelin sheath is formed by oligodendrocytes (OL) in central nervous system (CNS) cells or Schwann cells which wrap these myelin sheaths around the axon of a nerve cell. Oligodendrocytes are part of a separate non-neuronal cell population distributed throughout the CNS as part of the neuroglia. These are cells that are essential for the regular function of neurons, in the case of oligodendrocytes by forming the myelin sheaths around the axons, thereby increasing electric conduction of nerve impulses (Kandel et al., Principles of Neural Science, 3rd Ed., Elsevier 1991, p. 22). Therefore the identification and characterization of factors which are responsible for preventing the demyelination is very important for the molecular understanding of demyelinating diseases and for the development of therapeutic agents.

It is well known that NGF acts on different subtypes of neuronal cells. In the periphery NGF is a survival factor for sensory and sympathetic neurons (Levi-Montalcini, R. and Angeletti, P. U. (1963) Dev. Biol. 7: 653-659; Chun, L. L. Y. and P. H. Patterson (1977) J. Cell Biol. 75: 694-704; Chun, L. L. Y. and P. H. Patterson (1977) J. Cell Biol. 75: 705-711; Crain, S. M. and E. R. Peterson (1974) Brain Res. 79: 145-152.), in the central nervous system NGF is a survival factor for cholinergic neurons and prevents the degeneration of cholinergic neurons in the basal forebrain (Gage et al. (1988) J. Comp. Neurol. 269: 147-155; Hefti et al. (1986) J. Neurosci. 6: 2155-2162; Hefti et al. (1986) J. Brain Res. 293: 305-311.).

With the results of Althaus et al. a new characteristic of NGF was identified (Althaus et al. (1992) Neurosci. Lett. 135: 219-223, and International Application No. WO 93/03140). NGF induced proliferation and differentiation of oligodendrocytes, a non-neuronal cell population. These oligodendrocytes are specialized and the only cells in the central nervous system which are capable of producing myelin and wrapping the myelin sheaths around the axons. The oligodendrocytes and myelin sheaths are susceptible to attack by auto-immune

processes, e.g., multiple sclerosis. Therefore, Althaus indicates that the induction of remyelination could be an important step in a therapeutic approach for multiple sclerosis.

In the present invention, another new characteristic of NGF has been discovered. NGF is able to prevent demyelination of nerve fibers of the nervous system of a mammal, preferably of a human being, by influencing the immune system or the blood brain barrier (endothelial cells, T cells, macrophages, monocytes and microglia cells) At the moment the mechanism by which NGF is effective is not yet clear. But prevention of demyelination is a new and unexpected activity of NGF. Preferably, the effective amount of NGF or active NGF fragments is between 10 and 300 pg NGF/ml CSF (cerebrospinal fluid).

Koliatsos et al. discloses that NGF prevents the degeneration of cholinergic neurons in the basal forebrain. This finding is exclusively focused on NGF-sensitive nerve cells (neurons) in a small area of the brain, whereas the present invention is directed to the prevention of demyelination throughout the brain.

This approach is completely unrelated to the known effect of NGF on cholinergic neurons or other neuronal populations.

The object according to the present invention is achieved by a process for preventing the demyelination of nerve fibers in the nervous system of a human being, wherein said human being is treated with an amount of nerve growth factor (NGF) or active fragments of NGF elective to prevent demyelination.

L. Massacesi et al. have developed and extensively characterized a novel model of experimental allergic encephalomyelitis (EAE) in a small non-human primate (Massacesi, L. et al., Ann. Neurol. 37 (1995) 518-530). In contrast to most forms of acute EAE in rodents and in other non-human primates, EAE in the common marmoset Callithrix jacchus (C. jacchus) is a clinically mild, relapsing remitting disease characterized pathologically by early and prominent demyelination with astrogliosis that is highly reminiscent of human multiple sclerosis (MS). Thus, this unique laboratory model is most suitable for testing substances which are useful for the prevention of demyelination.

The early studies had the limited objective of exploring the feasibility of such treatment in an animal model that closely resembled human MS. In testing the present invention, acute demyelinating EAE was induced in marmosets by active immunization with 100 µg

recombinant rat myelin/oligodendrocyte glycoprotein (MOG) in adjuvant. Beginning 7 days after immunization, animals were treated with NGF or placebo (6μg/day) administered intracerebroventricularly by continuous infusion. Animals were monitored in a blinded fashion for clinical signs of EAE cerebrospinal fluid (CSF) pleocytosis (e.g., inflammation), and immune cellular and antibody responses, for a period of 28 days following immunization.

In the NGF-treated animals, clinical EAE was delayed and markedly suppressed in severity compared to the controls. Neuropathologic examination of the NGF-treated animals corroborated the observation of clinical protection; fewer and smaller perivascular inflammatory infiltrates accompanied only by minimal demyelination were seen in the treated animals. This was in contrast with the large perivascular foci of inflammation with extensive demyelination which are usually present at the acute phase of MOG-induced EAE and which were also observed in the control animals of this study. Surprisingly, the results have uncovered an unforeseen effect of NGF, namely protection against EAE. This effect could be mediated by interaction of NGF with the immune system of the periphery or via local mechanisms within the central nervous system, possibly suppression of inflammatory mediators such as cytokines or leukotrienes.

The term "NGF" or "active fragment of NGF" within the sense of the present invention refers to natural NGF, in particular mammalian NGF preferably natural human or murine NGF and all fragments or derivatives of NGF which have its desired biological activity, i.e., prevent the fiber demyelination of oligodendrocytes. Examples of NGF molecules which are suitable for the process according to the present invention are for instance NGF-β, NGF 2.5S or NGF 7S from the submaxillary gland of the mouse. These NGF molecules can, for example, be obtained commercially from Sigma (St. Louis, USA) or Boehringer Mannheim GmbH (Mannheim, DE). The process according to the present invention is preferably carried out with a human NGF, particularly preferably with human recombinant NGF-β. The production of an active NGF fragment by tryptic digestion of NGF is described by Mercanti et al. in Biochim. Biophys. Acta 496 (1977) 412-419. This fragment is composed of two linear oligopeptides which are linked by a disulfide bridge and contains the amino acid residues 10 to 25 and 75 to 88 of the amino acid sequence of NGF [according to the nomenclature of Angeletti and Bradshaw, Proc. Natl. Acad. Sci. USA 68 (1970) 2417-2421].

The present invention also concerns a pharmaceutical composition for the treatment of diseases in which a demyelination of nerve fibers occurs and which contains NGF or an

active fragment thereof as the active substance together with the usual pharmaceutical vehicles, auxiliary substances, fillers and diluents. The pharmaceutical composition preferably contains human NGF, especially human recombinant NGF-β. In addition, the composition can contain one or several pharmaceutically tolerated protease inhibitors, for example, aprotinin, preferably in a kit wherein NGF and said inhibitor are located in separate containers.

In order to produce pharmaceutical preparations, the composition according to the present invention can be processed with therapeutically acceptable vehicles. Suitable vehicles for the production of such solutions are water, polyols, sucrose, invert sugar and glucose. Suitable vehicles for injection solutions are water, alcohols, polyols, glycerol and vegetable oil.

In addition, the pharmaceutical preparations can contain preservatives, solvents, stabilizing agents, wetting agents, emulsifiers, salts for changing the osmotic pressure, buffers and, if desired, other therapeutic drugs.

Inflammatory toxic-metabolic or hypertoxic disorders may cause damage to the myelin sheaths. Examples of such disorders, or diseases, are:

Multiple Sclerosis:

- classical (Charcot type)
- acute multiple sclerosis (Marburg type)
- diffuse sclerosis (Schilder)
- neuroptic myelitis (Devic)
- concentrical sclerosis (Baló)

ADEM (acute disseminated encephalomyelitis and perivenous encephalomyelitis:

- (post- and parainfectious, post-vaccinal or "spontaneous")

Demyelination caused by virus:

- subacute sclerosing panencepohalitis (SSPE)
- progressive multifocal leucoencephalopathy (PML)

- AIDS-encephalopathy and -myelopathy
- tropical paralysis (HTLV I)

Demyelination caused by toxic metabolism:

- central pontine myelinolysis
- Marchiafava-Bignami syndrome
- funicular myelosis (vitamin B12 deficiency)

Demyelination caused by hypoxia/ischemia:

- subcortical arteriosclerotic encephalopathy (Binswanger's disease)
- post-hypoxic leucoencephalopathy

The Guillain-Barré syndrome (B. Vinken, Handbook of Clinical Neurology 7, Diseases of Nerves, Part I, Chapter 19 (1970) pp. 495 et seq.) is the most frequently observed type of peripheral polyneuritis.

Demyelination usually occurs subacutely, or even acutely, whereas slow development taking place over a number of weeks, or even months, is rarely observed. Hence, it is important that when polyneuritis has been diagnosed, treatment with NGF should be initiated immediately so as to prevent demyelination, as is described in the present invention. At the very onset of polyneuritis, as in Multiple Sclerosis, an inflammation of the optic nerve is usually observed. Thus, the present invention is also directed to the treatment of inflammatory diseases of the optic nerve. The action of NGF on the optic nerve is shown in Fig. 3.

Diseases in which a demyelination of nerve fibers occurs and which can be treated with the aid of the pharmaceutical composition according to the present invention can, for example, be caused by inflammation, autoimmune processes, enzymes or toxins. Examples of such diseases are, for instance, Multiple Sclerosis, slow virus encephalitis, various forms of myelitis or heavy metal poisoning. According to the invention it is preferred to administer NGF immediately after an inflammatory disease (causing further a demyelination) of an optic nerve is recognized.

The composition according to the present invention is preferably administered systemically. The administration can be carried out by methods familiar to a person skilled in the art, for

example, intrathecally, intravenously or subcutaneously. For the intrathecally or intravenous administration, NGF can be dissolved, for example, in physiological saline.

The addition of protease inhibitors, e.g., aprotinin, is not absolutely necessary when NGF is administered daily but does afford protection against proteases which could inactivate NGF. The preferred lower limit for the daily administered NGF dose is at a concentration between 0.05 µg and 5 µg/kg body weight . The administration of NGF is preferably carried out over a longer time period, i.e., longer than a day, preferably at least 48 hours.

The following examples, references and the figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

Brief Description of the Figures:

Figure 1a shows the experimental procedures for preventing acute EAE according to the present invention.

Figure 1b shows the clinical course of experimental autoimmune encephalomyelitis in placebo (Cytochrom C, n=2) and NGF (n=2) treated animals. The NGF treated animals showed a significant amelioration of the clinical score versus placebo treated animals.

Figure 1c shows the EAE (experimental allergic encephalomyelitis) reaction in four different marmosets. Marmosets 26.33.93 and 26.17.94 are treated on day 7 after immunization with placebo (cytochrome) whereas marmosets 26.29.94 and 26.30.92 are treated on day 7 after immunization with NGF.

Figure 2 is a photomicrograph of frontal sections through the brains of marmosets (Luxol Fast Blue Staining), depicting two representative areas from the prosencephalon and mesencephalon. The number of lesions (arrows point to examples in the photomicrographs) is lower in the NGF treated animal than in the marmoset receiving placebo-infusion of cytochrome C (magnification: 4x).

Figure 3 is a higher magnification of cross sections through the optic nerves of marmosets (Luxol Fast Blue-staining). Note the severe inflammation and demyelination in a cytochrome C-treated EAE-animal, in contrast to the absence of lesions in the marmoset receiving intraventricular NGF-infusion. Magnification: ca. 100X.

Preparation of Animals

1. Placement of intracerebroventricular catheters

A technique for implanting indwelling cannulas in the brain ventricles of marmosets has been developed. Seven days prior to immunization for EAE, surgery is carried out after the animal is anaesthetized with ketamine/midazolam (20 mg/kg). The skin above the skull is shaved and surgically disinfected with surgical scrub and ethyl alcohol. The animal is positioned in a stereotaxic table on a K-pad and a sterile field is created over the skull. A skin incision is made and the skull exposed. The dura meninges are exposed through a small hole drilled in the bone of the skull, in regard to the appropriate coordinates for the right lateral ventricle (according to a published atlas of marmoset brain anatomy). A 25 gauge 5 mm-long stainless steel guide containing a 35 gauge polycarbonate cannula is then inserted in the cerebral ventricle, and secured to the bone with 2 lateral screws and a thin layer of dental cement. A second skin incision is made in the right flank of the animal. A 25 gauge polyvinyl catheter is connected with the ventricular cannula and then tunneled under the skin to the flank incision. At this point the skull incision is closed with sutures and the flank end of the polyvinyl catheter is connected to the flow regulator of a mini osmotic Alza pump filled with saline. The flank incision is then closed and the animal monitored for recovery. Although no significant risk of infection has been reported using this technique in rodents and higher mammals, Clamoxyl at 10 mg/kg BID per os is administered as a systematic prophylactic procedure against secondary infection of the central nervous system.

2. Replacement of osmotic minipumps

For pump replacement, the animal is first sedated (ketamine/midazolam), the hair on one flank trimmed and the skin disinfected using surgical, sterile technique. The animal is placed on a K-pad to prevent hypothermia. A small skin incision (0.5 cm) is made on the flank and the pump connected with the intracerebroventrical catheter and inserted in the subcutaneous space, then the incision is closed with surgical staples. Although no infectious complication

has been observed using this technique, Clamoxyl at 10 mg/kg intramuscularly x 1 is administered prophylactically at the time of pump insertion. The size of the pump suitable for marmosets is the 200 µl capacity model 2002, i.e. the smallest available.

Example 1

Prevention of acute C. jacchus EAE with NGF

1. Immunizations

EAE is induced with 100 µg of rat recombinant myelin/oligodendrocyte glycoprotein (MOG) in complete Freund's adjuvant followed by intravenous administration of 10^{10} killed Bordetella Pertussis organisms on the day of immunization and again 48 hours later. In preparation for immunization, antigen and adjuvant are emulsified under sterile conditions. The animal is then anesthetized with keamine/midazolam and 100 µl of the mixture is injected intradermally into four sites in the shoulder and hip areas. Prior to injection the sites are shaved, cleaned three times with surgical scrub and then twice with ethyl alcohol. Bordetella Pertussis is injected slowly (over 5 minutes) after placement of a 21 gauge catheter in the popliteal vein using the same skin preparation technique. A second Bordetella Pertussis injection is given 48 hours later using the same technique.

2. Treatments

Beginning on day 7 after immunization (before the appearance of clinical signs) the animals receive either placebo (cytochrome) or NGF delivered via a cannula implanted in the lateral ventricle and connected by a mini catheter to an osmotic Alza mini pump implanted under the skin of the flank; the pump containing NGF or placebo is implanted on day 0 (to account for the dead volume of the mini catheter) and delivers 6±1 µl/day until day 28. The dose of NGF is 6 µg/day, determined on the basis of preliminary experiments in marmosets. Treatment is continued for a total of 21 days and the animals are euthanized (Figure 1a and table 2).

3. Observation of Clinical Course

Signs of EAE are monitored daily by blinded observers. Proliferative responses to myelin antigens are measured in blood on days 0, 14 and 28 after immunization. The CSF

inflammatory responses and the CSF concentrations of NGF are monitored at days 0, 14 and 28 after immunization.

4. Histologic examination

Neuropathologic examination of the brain and spinal cord is performed according to standard published techniques. Animals are euthanized at the end of the 28 day period and the nervous system perfused. Under deep pentobarbital anesthesia a thoracotomy is performed and a 14 gauge catheter is introduced and secured in the left ventricle. The right atrium is then opened and 200 ml of cold phosphate buffered saline are perfused through the heart. The descending aorta is then clamped in order to preserve spleen, inguinal lymph nodes, and the lower portion of the spinal cord as a supply of fresh or cryopreserved tissues for immunologic studies. Two hundred ml of a 2.5% solution of glutaraldehyde in phosphate buffer, pH 7.4 are then perfused as fixative. Brain hemispheres and spinal cord are dissected and after further fixation are prepared for histopathologic analysis according to our standard protocol. Eight 2.5 mm thick sections are cut in a plane perpendicular to the intercallosal line and embedded in paraffin for cutting and routine stains (hematoxylin/eosin and luxol fast blue). Some tissue is saved for processing thin (plastic) sections and electron microscopy, in order to obtain an ultrastructural analysis of myelin. Immunohistochemistry is performed on fixed tissues or on cryopreserved specimens from the caudal spinal cord, including staining with anti-MOG, anti-PLP and anti-MAG antibodies. In addition to ultrastructural analysis, these studies provide a valid assessment of the remyelinating process, if any, in and around the inflammatory lesions.

5. Cytokine gene expression in the central nervous system

These studies are carried out on fresh frozen sections of the spinal cord. Semi-quantitation of tumor necrosis factor (TNF-α), lymphotoxin (TNF-β), IL-2, IL-6, IL-10 and transforming growth factor- (TGF-β) are performed according to the protocol in use at the UCSF laboratory. Previous work has already established that the proinflammatory cytokine TNF-α likely plays a major role in promoting inflammation and demyelination in marmoset EAE. This proposed approach acts as a preliminary screen to determine whether the NGF-induced protection against EAE is mediated via modulation of local cytokines in the nervous system.

6. Treatment groups

There are two experimental groups used:

a) NGF, 6 µg/day intracerebroventricularly
b) Placebo (Cytochrome c), 6 g/day intracerebroventricularly

Treatments begin 7 days after immunization and are continued until day 28 after immunization.

List of References

Althaus et al., Neurosci. Lett. 135 (1992) 219-223
Angeletti and Bradshaw, Proc. Natl. Acad. Sci. USA 68 (1970) 2417-2421
Chun, L. L.Y., and Patterson, P. H., J. Cell Biol. 75 (1977) 694-704
Chun, L. L.Y., and Patterson, P. H., J. Cell Biol. 75 (1977) 705-711
Crain, S. M., and Peterson, E. R., Brain Res. 79 (1974) 145-152
Gage et al., J. Comp. Neurol. 269 (1988) 147-155
Hefti et al., J. Brain Res. 293 (1986) 305-311
Hefti et al., J. Neurosci. 6 (1986) 2155-2162
International Application No. WO 93/03140
Kandel et al., Principles of Neural Science, 3rd Ed., Elsevier 1991, p. 22
Levi-Montalcini, R., and Angeletti, P. U., Dev. Biol. 7 (1963) 653-659
Massacesi, L. et al., Ann. Neurol. 37 (1995) 518-530
Vinken, B., Handbook of Clinical Neurology 7, Diseases of Nerves, Part I, Chapter 19 (1970) pp. 495 et seq.

Patent Claims

1. A process for preventing the demyelination of nerve fibers in the nervous system of a human being wherein said human being is treated with an amount of nerve growth factor (NGF) or active fragments of NGF effective to prevent demyelination.

2. The process according to claim 1, wherein said fragments are selected from the group consisting of NGF 2.5S and NGF 7S.

3. The process according to claim 1, wherein said nerve growth factor is human recombinant NGF-β.

4. The process according to claim 1, further comprising the administration of at least one protease inhibitor in combination with said NGF.

5. The process according to claim 4, wherein said protease inhibitor is aprotinin.

6. The method according to claim 1, wherein said NGF is administered to a patient in need of such treatment and said NGF is administered in an amount sufficient to produce a concentration of NGF or an active fragment of NGF between 0.05 μg and 5 μg/kg body weight.

7. A pharmaceutical composition for the treatment of diseases in which demyelination of nerve fibers occurs, comprising NGF or an active fragment thereof in combination with a pharmaceutical vehicle, auxiliary substance, filler or diluent.

8. The composition according to claim 7, wherein said fragment is selected from the group consisting of NGF 2.5S and NGF 7S.

9. The composition according to claim 7, wherein said NGF is human recombinant NGF-β.

10. The composition according to claim 7, further comprising at least one protease inhibitor in an amount sufficient to prevent inactivation of NGF by proteases.

11. The composition according to claim 10, wherein said protease inhibitor is aprotinin.

12. A process for preventing further demyelination in a patient having a disease in which a demyelination of nerve fibers occurs, comprising administering an amount of nerve growth factor or an active fragment thereof effective to prevent further demyelination.

13. The process according to claim 12, wherein the nerve growth factor is administered intravenously or intrathecally.

14. A method for preventing further demyelination in a patient having an inflammatory disease of the optic nerve, comprising administering an effective amount of NGF or an active fragment of NGF selected from the group consisting of NGF 2.5S and NGF 7S.

15. The method according to claim 14, wherein said effective amount of NGF or an active fragment of NGF is between 10-300 pg NGF/ml blood.

16. A kit for preventing further demyelination of nerve fibers, comprising NGF and at least one protease inhibitor in separate containers.

Fig. 1a

Prevention of acute EAE



Days	-7	0	7	14	21	28	35
T-cell and ab reactivity		X		X		X	
CSF		X		X		X	
Histology						X	

Fig. 1b


Effects of NGF on clinical EAE
(means/SEM)
clinical score
16
14
12
10
8
6
4
2
0
0
4
8
12
16
20
24
28
A (NGF)
B (Cytochrome)
Days after immunization


Fig. 1c
26.33.93 B
26.17.94 B
26.29.94 A
26.30.92 A
Begin Infusion
Clinical Score
Days after Immunization
0
3
6
9
12
15
18
21
0
4
8
12
16
20
24
28

Fig. 2

Fig. 3



Attorney Docket No.: 305T-900300US
Client Reference No.: **SF2000-012**

DECLARATION

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **NGF FOR THE PREVENTION OF DEMYELINATION IN THE NERVOUS SYSTEM** the specification of which __ is attached hereto or __x__ was filed on **April 8, 1998** as Application No. **09/529,369**.

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
AU	72,149/98	04/08/1998	
CA	2,286,137	04/08/1998	
WO	PCT/EP98/02029	04/08/1998	

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
08/833,959	April 11, 1997	PENDING

Full Name of Inventor 1:	Full Name: **Ilse Bartke**		
Residence & Citizenship:	City: **Mannheim**	State/Foreign Country: **Germany**	Country of Citizenship: **Germany**
Post Office Address:	Post Office Address: **Sandhofer Straße 116 D-68305 Mannheim**		
Full Name of Inventor 2:	**Jürgen Unger**		
Residence & Citizenship:	City: **Landshut**	State/Foreign Country: **Germany**	Country of Citizenship: **Germany**
Post Office Address:	Post Office Address: **Sperberweg 5 D-84036 Landshut**		
Full Name of Inventor 3:	Full Name: **Claude Genain**		
Residence & Citizenship:	City: **Mill Valley**	State/Foreign Country: **California**	Country of Citizenship: **France**
Post Office Address:	Post Office Address: **568 Marin Avenue Mill Valley, CA 94941**		
Full Name of Inventor 4:	Full Name: **Stephen Hauser**		
Residence & Citizenship:	City: **Ross**	State/Foreign Country: **California**	Country of Citizenship: **USA**
Post Office Address:	Post Office Address: **P.O. Box 1588 Ross, CA 94957**		

Attorney Docket No.: 305T-900300US
Client Reference No.: SF2000-012

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3
Ilse Bartke		
Ilse Bartke	**Jürgen Unger**	**Claude Genain**
Date 05/14/2001	Date	Date

Signature of Inventor 4
Stephen Hauser
Date

(Modified) PTO/SB/81 (11-96)
Approved for use through 6/30/99. OMB 0651-0035

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT, NOT ACCOMPANYING APPLICATION

Application Number	09/529,369
Filing Date	April 8, 1998
First Named Inventor	Ilse Bartke
Group Art Unit	Not yet known
Examiner Name	Not yet known
Attorney Docket Number	305T-900300US

I hereby appoint:

X Practitioners at Customer Number 22798
Type Customer Number Here

OR

___ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

X The above-mentioned Customer Number.

THAT IS:

Firm or Individual Name	Law Offices of Jonathan Alan Quine				
Address	P.O. Box 458				
Address					
City	Alameda	State	CA	Zip	94501
Country	United States				
Telephone	(510) 337-7871	Fax	(510) 337-7877		

I am the

___ Applicant.

X Assignee of record of the entire interest (*Certificate under 37 CFR 3.73(b) is enclosed*)

SIGNATURE of Applicant or Assignee of Record

Name	Susan Y. Nakashima
Signature	Susan Y. Nakashima
Date	April 9, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: June 4, 2001

Typed or printed name	Richard Park		
Signature	Richard Park	Date	6/4/01

Full Name of Inventor 1:	Full Name: **Ilse Bartke**		
Residence & Citizenship:	City: **Mannheim**	State/Foreign Country: **Germany**	Country of Citizenship: **Germany**
Post Office Address:	Post Office Address: **Sandhofer Straße 116 D-68305 Mannheim**		
Full Name of Inventor 2:	**Jürgen Unger**		
Residence & Citizenship:	City: **Landshut**	State/Foreign Country: **Germany**	Country of Citizenship: **Germany**
Post Office Address:	Post Office Address: **Sperberweg 5 D-84036 Landshut**		
Full Name of Inventor 3:	Full Name: **Claude Genain**		
Residence & Citizenship:	City: **Mill Valley**	State/Foreign Country: **California**	Country of Citizenship: **France**
Post Office Address:	Post Office Address: **568 Marin Avenue Mill Valley, CA 94941**		
Full Name of Inventor 4:	Full Name: **Stephen Hauser**		
Residence & Citizenship:	City: **Ross**	State/Foreign Country: **California**	Country of Citizenship: **USA**
Post Office Address:	Post Office Address: **P.O. Box 1588 Ross, CA 94957**		

Attorney Docket No.: 305T-900300US
Client Reference No.: SF2000-012

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3
Ilse Bartke	**Jürgen Unger**	**Claude Genain**
Date	Date 05/15/2001	Date

Signature of Inventor 4
Stephen Hauser
Date

Full Name of Inventor 1:	Full Name: **Ilse Bartke**		
Residence & Citizenship:	City: **Mannheim**	State/Foreign Country: **Germany**	Country of Citizenship: **Germany**
Post Office Address:	Post Office Address: **Sandhofer Straße 116 D-68305 Mannheim**		
Full Name of Inventor 2:	**Jürgen Unger**		
Residence & Citizenship:	City: **Landshut**	State/Foreign Country: **Germany**	Country of Citizenship: **Germany**
Post Office Address:	Post Office Address: **Sperberweg 5 D-84036 Landshut**		
Full Name of Inventor 3:	Full Name: ~~**Claude Genain**~~		
Residence & Citizenship:	City: ~~**Mill Valley**~~	State/Foreign Country: **California**	Country of Citizenship: **France**
Post Office Address:	Post Office Address: **568 Marin Avenue Mill Valley, CA 94941**		
Full Name of Inventor 4:	Full Name: **Stephen Hauser**		
Residence & Citizenship:	City: **Ross**	State/Foreign Country: **California**	Country of Citizenship: **USA**
Post Office Address:	Post Office Address: **P.O. Box 1588 Ross, CA 94957**		

Attorney Docket No.: 305T-900300US
Client Reference No.: SF2000-012

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3
Ilse Bartke	**Jürgen Unger**	**Claude Genain**
Date	Date	Date April 9/01

Signature of Inventor 4
Stephen Hauser
Date

Full Name of Inventor 1:	Full Name: **Ilse Bartke**		
Residence & Citizenship:	City: **Mannheim**	State/Foreign Country: **Germany**	Country of Citizenship: **Germany**
Post Office Address:	Post Office Address: **Sandhofer Straße 116 D-68305 Mannheim**		
Full Name of Inventor 2:	**Jürgen Unger**		
Residence & Citizenship:	City: **Landshut**	State/Foreign Country: **Germany**	Country of Citizenship: **Germany**
Post Office Address:	Post Office Address: **Sperberweg 5 D-84036 Landshut**		
Full Name of Inventor 3:	Full Name: **Claude Genain**		
Residence & Citizenship:	City: **Mill Valley**	State/Foreign Country: **California**	Country of Citizenship: **France**
Post Office Address:	Post Office Address: **568 Marin Avenue Mill Valley, CA 94941**		
Full Name of Inventor 4:	Full Name: **Stephen Hauser**		
Residence & Citizenship:	City: **Ross**	State/Foreign Country: **California**	Country of Citizenship: **USA**
Post Office Address:	Post Office Address: **P.O. Box 1588 Ross, CA 94957**		

Attorney Docket No.: 305T-900300US
Client Reference No.: SF2000-012

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3
Ilse Bartke	**Jürgen Unger**	**Claude Genain**
Date	Date	Date

Signature of Inventor 4
Stephen Hauser
Date 4/10/01

United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division

Application deficiencies found during scanning:

☐ Page(s)_____of_____ were not present for scanning. (Document title)

☐ Page(s)_____of_____were not present for scanning. (Document title)

☑ ***Scanned copy is best available.*** drawings